These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2409674)

  • 1. [Monoclonal antibodies in the radioimmunological diagnosis of malignant tumors of the gastrointestinal tract and ovaries].
    Tkacheva GA; Blokhina NG; Klimenkov AA; Kozachenko VP
    Vopr Onkol; 1985; 31(5):36-42. PubMed ID: 2409674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
    Sevelda P; Salzer H; Dittrich C; Spona J
    Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ganglioside and carcinoembryonic antigens in the diagnosis of malignant tumors of the gastrointestinal tract].
    Ivanov PK; Samoĭlenko VM
    Vopr Onkol; 1984; 30(9):55-9. PubMed ID: 6495695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
    Chen DX; Schwartz PE; Li XG; Yang Z
    Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.
    Bray KR; Koda JE; Gaur PK
    Cancer Res; 1987 Nov; 47(22):5853-60. PubMed ID: 2444335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
    Suzuki H; Teshima K; Noda K
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
    Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
    Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
    Ohkura H; Sakawaki T
    Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of CA 50 and CA 19-9 tumor markers in benign and malignant diseases of the upper gastrointestinal tract].
    Heptner G; Domschke S; Schneider MU; Siegfried W; Domschke W
    Dtsch Med Wochenschr; 1986 Mar; 111(10):374-8. PubMed ID: 2419074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preliminary application of carbohydrate antigen CA-50 radioimmunoinhibition test in diagnosing and monitoring cancers].
    Chen ZZ; Fan ZF; Su P
    Zhonghua Zhong Liu Za Zhi; 1987 Nov; 9(6):436-8. PubMed ID: 2838242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application of monoclonal antibody OC 125 in gynecological oncology].
    Wu AR; Wang EY; Wang XX; Jia XH; Li L
    Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CA 19-9 in early cancers of the bronchi. Comparison with the carcinoembryogenic antigen].
    Vindimian M; Lafitte JJ; Wattre P
    Biomed Pharmacother; 1987; 41(4):191-5. PubMed ID: 3476162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of sialyl Tn antigen in patients with gynecologic tumors.
    Inoue M; Ogawa H; Nakanishi K; Tanizawa O; Karino K; Endo J
    Obstet Gynecol; 1990 Jun; 75(6):1032-6. PubMed ID: 2342728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA-125: An evaluation.
    Nuss R; Swor MG; Benrubi MD
    J Fla Med Assoc; 1987 May; 74(5):329-32. PubMed ID: 2440975
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
    Crombach G; Zippel HH; Würz H
    Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CA 19-9 in benign diseases of the gastrointestinal tract].
    Klapdor R
    Dtsch Med Wochenschr; 1986 Jun; 111(26):1039. PubMed ID: 3459644
    [No Abstract]   [Full Text] [Related]  

  • 17. [Serum levels and clinical evaluation of CA 19-9 in various diseases].
    Toyama K; Noto M; Sakaguchi T; Adachi K; Mitomi H; Okada N; Ootaka H; Nakazawa H; Hara E
    Gan No Rinsho; 1985 Mar; 31(3):293-8. PubMed ID: 2582158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract].
    Klapdor R; Greten H
    Dtsch Med Wochenschr; 1984 Dec; 109(50):1935-9. PubMed ID: 6210188
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer.
    Zurawski VR; Broderick SF; Pickens P; Knapp RC; Bast RC
    Obstet Gynecol; 1987 Apr; 69(4):606-11. PubMed ID: 2434895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with the tumor marker Ca 19-9 in an unselected group of more than 300 tumor patients.
    Souchon R; Koppenhagen K; Souchon MF; Matthes M; Boese-Landgraf J; Fitzner R; Baer U
    Cancer Detect Prev; 1985; 8(1-2):101-9. PubMed ID: 3864534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.